Thrombosis News and Research

Latest Thrombosis News and Research

Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy.

31 Aug 2009

Intermediate dosages of otamixaban reduce acute coronary complications

30 Aug 2009

Inhibitor Education Summits to address pertinent topics regarding hemophilia

More than 160 families of patients living with a rare form of hemophilia are coming together at educational summits sponsored this fall by the National Hemophilia Foundation (NHF) and the Center for Biomedical Continuing Education (CBCE). For the fifth year, the Inhibitor Education Summits will connect patients and their families with expert healthcare professionals and fellow patients to address pertinent topics such as effective pain management, exercise and nutrition, financial security, and psychological wellbeing.

29 Aug 2009

Thrombogenics issues business update and half year results

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

28 Aug 2009

New rule from CMS for improving stroke patient care in hospitals

A new rule from the U.S. Centers for Medicare and Medicaid Services (CMS Final FY 2010 Rule) focuses on improving stroke patient care in hospitals. Beginning 2010, hospitals submitting Medicare claims for stroke must let CMS know if they participate in a database registry for stroke care, such as that maintained by the American Heart Association/American Stroke Association's Get With The Guidelines-Stroke (GWTG-Stroke) quality improvement initiative.

28 Aug 2009

Prevention and eradication of FVIII antibodies could improve hemophilia treatment

Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.

27 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

Research study concludes the difference in mortality between men and women depending on the type of ACS

A new study from NYU School of Medicine found that women may have a slightly higher risk of death than men in the thirty days following an acute coronary syndrome (ACS), but that these differences appear to be attributable to factors such as severity and type of ACS.

26 Aug 2009

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).

26 Aug 2009

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Portola Pharmaceuticals, Inc. today announced two oral presentations at the European Society of Cardiology (ESC) Congress 2009 in Barcelona, Spain, that will feature its investigational antiplatelet drug elinogrel, a P2Y12 ADP receptor antagonist that is currently in Phase II clinical development with Novartis, Portola's development and commercialization partner.

25 Aug 2009

Angiotech Pharmaceuticals plans US launch of Option Inferior Vena Cava Filter

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced the commercial launch of the Option(TM) Inferior Vena Cava (IVC) Filter in the United States, following FDA 510(k) clearance in June and a limited pre-launch in July. Angiotech holds exclusive worldwide rights to market and distribute the Option IVC Filter, which it obtained in a license agreement with privately held Rex Medical, LP (Rex Medical), as announced in March 2008.

20 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

New type of anti-clotting drug called Apixaban

The dean of the University of Oklahoma College of Public Health and a team of scientists worldwide have found a better way to prevent deadly blood clots after joint replacement surgery - a major problem that results in thousands of unnecessary deaths each year. The research appears this week in the New England Journal of Medicine.

11 Aug 2009

Decode Genetics announces Q2 2009 financials

deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended June 30, 2009. A conference call to discuss these results and recent developments in the company's business will be webcast live tomorrow, Tuesday, August 11, at 8:00am Eastern Daylight Time/12 noon GMT/1pm British Summer Time (details below).

10 Aug 2009

New online tool to help nurses prevent the 10 "Never Events"

Elsevier, a world leader in healthcare and medical publishing and online solutions, today announced the availability of a new online tool within Mosby's Nursing Consult designed to help nurses prevent the 10 "Never Events" identified by the Centers for Medicare and Medicaid Services (CMS) in an October 2008 fact sheet.

10 Aug 2009

New drug promises to reduce damage from a heart attack

Research into a new drug by Australian heart experts has found that it can dramatically reduce heart muscle damage after a heart attack.

28 Jul 2009

New drug may reduce heart attack damage

A novel drug that targets a master disease-causing gene can dramatically reduce heart muscle damage after a heart attack and may lead to significantly improved patient outcomes, researchers at the University of New South Wales (UNSW) have shown.

22 Jul 2009

Why oral contraceptives fail for obese women

Researchers have identified a potential biological mechanism that could explain why oral contraceptives may be less effective at preventing pregnancy in obese women, as some epidemiological studies have indicated.

14 Jul 2009

New peripherally inserted central catheter mimics nature

A novel coating being used on a new peripherally inserted central catheter (PICC) from r4 Vascular mimics the cell layer found on natural tissue surfaces.

30 Jun 2009

Drug-eluting stents more effective than bare-metal stents in heart attack patients

NewYork-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation (CRF), announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine.

26 May 2009

Thrombosis News and Research

Latest Thrombosis News and Research

Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

Intermediate dosages of otamixaban reduce acute coronary complications

Inhibitor Education Summits to address pertinent topics regarding hemophilia

Thrombogenics issues business update and half year results

New rule from CMS for improving stroke patient care in hospitals

Prevention and eradication of FVIII antibodies could improve hemophilia treatment

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Research study concludes the difference in mortality between men and women depending on the type of ACS

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Angiotech Pharmaceuticals plans US launch of Option Inferior Vena Cava Filter

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

New type of anti-clotting drug called Apixaban

Decode Genetics announces Q2 2009 financials

New online tool to help nurses prevent the 10 "Never Events"

New drug promises to reduce damage from a heart attack

New drug may reduce heart attack damage

Why oral contraceptives fail for obese women

New peripherally inserted central catheter mimics nature

Drug-eluting stents more effective than bare-metal stents in heart attack patients

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Thrombosis News and Research

Latest Thrombosis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in